| Added by | mollevi |
|---|---|
| Group name | EquipeMY |
| Item Type | Journal Article |
| Title | Multicenter evaluation of a novel ROS1 immunohistochemistry assay (SP384) for detection of ROS1 rearrangements in a large cohort of lung adenocarcinoma patients |
| Creator | Hofman et al. |
| Author | Véronique Hofman |
| Author | Isabelle Rouquette |
| Author | Elodie Long-Mira |
| Author | Nicolas Piton |
| Author | Emmanuel Chamorey |
| Author | Simon Heeke |
| Author | Jean Michel Vignaud |
| Author | Clémence Yguel |
| Author | Julien Mazières |
| Author | Anne-Laure Lepage |
| Author | Frédéric Bibeau |
| Author | Hugues Begueret |
| Author | Sandra Lassalle |
| Author | Salomé Lalvée |
| Author | Katia Zahaf |
| Author | Jonathan Benzaquen |
| Author | Michel Poudenx |
| Author | Charles-Hugo Marquette |
| Author | Jean-Christophe Sabourin |
| Author | Marius Ilié |
| Author | Paul Hofman |
| Abstract | INTRODUCTION: The detection of a ROS1 rearrangement in advanced and metastatic lung adenocarcinoma (LUAD) lead to a targeted treatment with tyrosine kinase inhibitors, with favorable progression-free survival and overall survival of the patients. Thus, it is mandatory to screen for the ROS1 rearrangement in all these patients. ROS1 rearrangements can be detected using break-apart fluorescence in situ hybridization (FISH), which is the "gold standard"; however, ROS1 immunohistochemistry (IHC) can be used as a screening test since it is widely available, easy and rapid to perform, and cost-effective. METHODS: We evaluated the diagnostic accuracy and inter-pathologist agreement of two anti-ROS1 IHC clones, SP384 (Ventana, Tucson, AZ) and D4D6 (Cell Signaling, Danvers, MA), in a training cohort of 51 positive ROS1 FISH LUAD cases, and then in a large validation cohort of 714 consecutive cases of LUAD from six routine molecular pathology platforms. RESULTS: In the two cohorts, the SP384 and D4D6 clones demonstrate variable sensitivity and specificity rates on the basis of two cutoff points ?1+ (all % tumor cells and ?2+ (>30% stained tumor cells). In the validation cohort, the D4D6 yielded the best accuracy for the presence of a ROS1 rearrangement by FISH. Inter-pathologist agreement was moderate to good (ICC, 0.722-0.874) for the D4D6 clone and good to excellent (ICC, 0.830-0.956) for the SP384 clone. CONCLUSIONS: ROS1 IHC is an effective screening tool for the presence of ROS1 rearrangements. However, users must be acutely aware of the variable diagnostic performance of different anti-ROS1 antibodies prior to implementation into routine clinical practice. |
| Publication | Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer |
| Date | Apr 15, 2019 |
| Journal Abbr | J Thorac Oncol |
| Language | eng |
| DOI | 10.1016/j.jtho.2019.03.024 |
| ISSN | 1556-1380 |
| Library Catalog | PubMed |
| Extra | PMID: 30999109 |
| Tags | Adenocarcinoma of Lung, Biomarkers, Tumor, clinic, D4D6, FISH, Fluorescence in situ hybridization, Follow-Up Studies, Gene Rearrangement, Humans, Immunohistochemistry, In Situ Hybridization, Fluorescence, lung adenocarcinoma, Lung Neoplasms, Prognosis, Protein-Tyrosine Kinases, Proto-Oncogene Proteins, Retrospective Studies, ROS1, SP384 |
| Date Added | 2019/05/14 - 08:06:59 |
| Date Modified | 2020/07/24 - 16:15:17 |
| Notes and Attachments | PubMed entry (Attachment) PubMed entry (Attachment) Texte intégral (Attachment) |
Institut de Recherche en Cancérologie de
